2023 World Conference on Lung Cancer (Posters)-EP03.06. KRAS-B: Molecular Epidemiology and Clinical Outcomes of KRAS-Mutant Non-small Cell Lung Cancer (NSCLC) in Brazil

EP03.06. KRAS-B: Molecular Epidemiology and Clinical Outcomes of KRAS-Mutant Non-small Cell Lung Cancer (NSCLC) in Brazil - PDF(Abstract)

Back to course

Pdf Summary

This abstract summarizes a study conducted in Brazil on the molecular epidemiology and clinical outcomes of KRAS-mutant non-small cell lung cancer (NSCLC). KRAS mutations are the most common oncogene drivers in NSCLC and are associated with tobacco exposure and a poor prognosis. The study aimed to provide real-world data on KRAS mutations using next-generation sequencing (NGS) panels and evaluate clinical outcomes.<br /><br />The study included 533 NSCLC patients tested with the GS180 panel from January 2022 to December 2022. Of these patients, 140 had KRAS mutations, with KRAS G12C being the most common variant. The study also analyzed the frequency of co-mutations with KRAS, finding that TP53, STK11, and KEAP1 had the highest co-mutation rates. PD-L1 expression was found to be 1% in over half of the KRAS-mutant cases.<br /><br />In terms of patient characteristics, the median age at diagnosis was 73 years, and the majority of patients were female, white, and had a history of tobacco exposure. Most patients had locally advanced or metastatic NSCLC with adenocarcinoma histology. The first-line treatment consisted of a combination of chemotherapy and immunotherapy for the majority of patients.<br /><br />The primary endpoint of the study was overall survival (OS) in the KRAS G12C locally advanced/metastatic population. The median OS from the start of first-line palliative therapy was 15.0 months for KRAS G12C patients, 17.2 months for other KRAS-mutant patients, and 19.4 months for KRAS wild-type patients.<br /><br />In conclusion, the study found similar incidence rates of KRAS mutations in NSCLC compared to national data. KRAS G12C was the predominant mutation, and TP53 was the most frequent co-mutation. Brazilian KRAS G12C patients had numerically worse metastatic overall survival, but few patients received targeted therapy. Longer follow-up is needed to further compare the different populations.

Asset Subtitle

Pedro De Marchi

Meta Tag

Speaker Pedro De Marchi

Topic Tumor Biology: Translational Biology - Translational Therapeutics

Keywords

molecular epidemiology

clinical outcomes

KRAS-mutant

non-small cell lung cancer

NSCLC

oncogene drivers

tobacco exposure

poor prognosis

next-generation sequencing

NGS panels